Objective: Most low-trauma fractures occur among women with osteopenic bone mineral density (BMD), a population considered to have moderate absolute fracture risk. Our purpose was to refine the fracture risk prediction in women with osteopenic BMD to determine the subgroups at lowest and highest risk.
S tudies have consistently reported that the highest number of fractures in a given population occurs in those with osteopenic or normal bone mineral density (BMD). 1, 2 In fact, the National Osteoporosis Foundation has singled out those with osteopenic BMD as a population in which fracture risk assessment is merited. 3 Nevertheless, appropriate prevention and treatment strategies for these individuals are uncertain. 4 A key therapeutic dilemma in the management of patients with osteopenia is that absolute fracture risk is typically assessed to be in the Bmoderate[ category. As a result, recent studies have focused on identifying clinical risk factors that may be used together with BMD to improve fracture prediction in this group with a high frequency of fractures.
Several clinical risk factors, in addition to age and BMD, have been identified to predict fracture. Risk factors for fracture identified by the World Health Organization (WHO) collaborating center based on meta-analysis include previous fracture, body mass index, smoking, alcohol use, rheumatoid arthritis, glucocorticoid use, and parental history of hip fracture. 5 Indeed, inclusion of these clinical risk factors in a prediction model improves the estimates of 10-year absolute fracture risk 5 and forms the basis of the WHO FRAX calculators. 6 Other variables shown to be associated with fracture risk include change in height, change in weight, inflammatory bowel disease, kidney disease, health-related quality of life, 7 and previous falls. 8 It is important to note that most studies on fracture include women with osteoporotic BMD; hence, it is possible that the risk factors and model parameters might not be generalizable to those with better BMD. As well, most models focus on factors that increase fracture risk but do not examine factors such as overall good health that may indicate reduced fracture risk. Including such risk factors may be important to ensure that those at lower risk of clinical fracture can forego unnecessary follow-up and treatment. Finally, calibration of models in a general population may result in a narrow range of risk for those with osteopenic BMD, and model performance may be largely determined by separation of the high risk (osteoporotic BMD) from the low risk (normal BMD).
The aim of the current study was to determine the relative importance of clinical risk factors for fracture among women with osteopenia and to incorporate the most important independent risk factors in a new model specific to these women.
METHODS

Participants
We included women 50 to 90 years old, participating in an ongoing cohort study, the Canadian Multicentre Osteoporosis Study (CaMos), with follow-up fracture data and a baseline femoral neck BMD T score between j1 and j2.5. There were 6,539 women at baseline; 4,092 women met the age and follow-up criteria; 2,588 women had the requisite osteopenic BMD and were included in the study.
A description of the CaMos, together with associated publications, can be found on the study Web site at www.camos.org. Briefly, eligible participants were at least 25 years old at the start of the study and lived within a 50-km radius of one of nine Canadian cities (St John's, Halifax, Quebec City, Toronto, Hamilton, Kingston, Saskatoon, Calgary, and Vancouver). Households were randomly selected from a list of residential telephone numbers, and participants were randomly selected from eligible household members. Of those selected, 42% agreed to full participation with complete baseline interview. Ethics approval was granted through McGill University and the appropriate ethics review boards for each participating center.
Data collection
At baseline in 1995-1996, participants were given a standardized interviewer-administered questionnaire (CaMos questionnaire, copyright 1995), which assessed demographics, general health, nutrition, medication use, and medical history. The questionnaire was designed to capture detailed information about risk factors for fractures, including all previous fractures (fracture site, date, and circumstances), family history of osteoporosis/fracture, and falls in the past month. Participants completed the Medical Outcomes Trust 36-Item Health Survey (SF-36). We used the standardized physical component SF-36 score. We also used the response to the SF-36 question BIn general, would you say your health is: excellent, very good, good, fair, poor?[ as a measure of general health. Participants had a baseline clinical assessment that included measurement of height, weight, and BMD. BMD T scores were based on published reference standards for Canadians. 9 A more detailed description of BMD methods appears below. Follow-up visits were scheduled in the third year for those between 40 and 60 years old and in the 5th and 10th year for everyone. The follow-up visits included an interviewer-administered questionnaire together with measured height, weight, and BMD.
Bone mineral density
BMD was measured at baseline. Seven centers used Hologic densitometers and two centers used Lunar densitometers. All Lunar measurements were converted to equivalent Hologic values using standard reference formulas. 10 Scans were reanalyzed centrally to ensure proper positioning of the regions of interest. Longitudinal calibration was monitored daily using a manufacturer-specific phantom. Seven of the nine machines remained within the 1% limit, and two required one-time adjustments. A single European spine phantom was circulated across study sites, and the measurements were used to cross-calibrate machines. An estimate of the variability in human data can be obtained from the duplicate measurements taken on a group of 50 participants during an upgrade from a Hologic QDR 1000 to a GE Lunar Prodigy in Toronto. The reproducibility of the duplicate measurements is reflected in the magnitude of the spread of data about the line of regression; in this case, the residual SD was only 0.031.
Fracture assessment
Self-reported incident clinical fractures were identified by yearly postal questionnaire or at the scheduled interview (years 3 and 5). Confirmation and further fracture information was routinely gathered using a structured interview that included date, fracture site, circumstances leading to fracture, radiography report (if obtainable), and clinical treatment. Lowtrauma fractures were those that occurred without trauma or from a fall of standing height or less. The main outcome was low-trauma fracture of any skeletal site except the skull, face, hands, ankles, and feet.
Statistical methods
We used logistic regression models to determine the association between clinical risk factors (assessed at baseline) and incident low-trauma fracture between baseline and year 5. We derived several models for the prediction of fracture risk. There were two comparison models: model 1, including age and BMD; and model 2, including the WHO risk factors age, BMD, prior fracture, parental history of fracture, body mass index, current smoking, alcohol intake, rheumatoid arthritis, and use of glucocorticoids. 5 Variables were assessed for inclusion in a prediction model using the Bayesian Information Criterion. 11 The Bayesian Information Criterion is a single parameter that allows the comparison of non-nested models. Age and BMD were included in all models. For the construction of the new model, we considered the following additional variables: prior fracture (low-trauma clinical fracture after age 50 y), parental history of fracture, body mass index, smoking, alcohol intake, rheumatoid arthritis, use of glucocorticoids, physical health status (SF-36 physical health summary score), general health (from the SF-36), falls in the month before the baseline, height loss (maximal adult height minus current height), weight loss (maximal adult weight minus current weight), weight cycling (number of times lost/gained Q20 lb), vertebral deformity, age of menarche, age of menopause, use of antiresorptives (hormone therapy, bisphosphonates, raloxifene, and calcitonin), and specified comorbidities (heart disease, diabetes, hypertension, osteoarthritis, rheumatoid arthritis, inflammatory bowel disease, kidney disease, liver disease, stroke, neuromuscular disease, breast cancer, uterine cancer, and eating disorders).
We assessed for linearity in continuous variables and statistical interaction between pairs of continuous variables and between age and all other variables. For variables that were highly correlated, we included only one of the variables into the model selection process at a time. Our first derived model (model 3) included the SF-36 physical health summary score, a measure that is not readily available in clinical practice. Therefore, we repeated the model selection process, replacing this measure with self-reported general health to obtain a more usable model (model 4). Model fit was assessed using the Hosmer-Lemeshow test. Internal validation was done using bootstrap samples of the study population. Model comparison was done using gradient of risk, area under receiver operator curve (AUC), and net reclassification index (NRI). 12 For the NRI, we considered three categories of 5-year fracture risk for each model as clinically relevant: low (0%-5%), moderate (5%-10%), and high (910%). We used the Kaplan-Meier analysis to estimate absolute 5-and 10-year risk of clinical fracture within low-, moderate-, and high-risk categories. Analysis was performed using Stata version 9.2.
RESULTS
The baseline characteristics of the 2,588 women in the study sample are given in Table 1 . A total of 214 women had at least one clinical low-trauma fracture within 5 years, and the overall 5-year fracture risk in the cohort was 8.3%. The breakdown of fracture risk by age group was 5.1% (28/548) among women 50 to 60 years old, 6.6% (70/1,065) among women 60 to 70 years old, 11.2% (91/816) among women 70 to 80 years old, and 15.7% (25/159) among women 80 to Table 2 ). The predicted absolute 5-year risk of clinical lowtrauma fracture by selected low-risk covariate patterns based on all models is shown in Table 3 . The minimum absolute risk in models 1 and 2 was notably higher within each age and BMD stratum than the absolute risk derived for those in excellent physical health (model 3) or excellent general health (model 4). The table provides the lowest risk for a given age and BMD as individuals with different risk profile (ie, including additional risk factors) will have higher risk. It is also clear that the risk gradient for age and BMD was higher in the first two models compared with the latter two models.
Model 3
We found an increased fracture risk among those with lower BMD (odds ratio [OR], 1.61; 95% CI, 1.11-2.32) per change in BMD T score within the osteopenic range (eg, from j1 to j2), those with prior low-trauma fracture (OR, 2.00; 95% CI, 1.41-2.84), those with worse physical health (OR, 1.40; 95% CI, 1.22-1.60) for each 10-point decrease in the SF-36 physical health summary score, and those with height loss (OR, 1.40; 95% CI, 1.12-1.75) for each 5-cm height loss. Age, included as an a priori specified risk factor in all models, was associated with increased risk that was not statistically significant (OR, 1.15; 95% CI, 0.94-1.41) per decade.
Model 4
Each category of lower general health was associated with increased fracture risk (OR, 1.35; 95% CI, 1.15-1.59) per category change. We found an increased fracture risk among those with lower BMD (OR, 1.53; 95% CI, 1.06-1.50) per 1 unit change in BMD T score, those with prior low-trauma fracture (OR, 2.06; 95% CI, 1.46-2.92), and those with height loss (OR, 1.40; 95% CI, 1.12-1.75) for each 5-cm height loss. Age was associated with increased fracture risk, but this association was statistically marginal (OR, 1.23; 95% CI, 1.00-1.50) per decade.
We compared the distributions of predicted risk by computing the gradient of risk per SD of risk scores and found a risk gradient of 1.55 for model 1 (base model), 1.75 for model 2 (WHO risk factors), 1.88 for model 3 (including the SF-36), and 1.84 for model 4 (including general health). Furthermore, model 1 had an AUC of 0.62 (95% CI, 0.58-0.68), model 2 had an AUC of 0.67 (95% CI, 0.63-0.71), model 3 had an AUC of 0.69 (95% CI, 0.65-0.72), and model 4 had an AUC of 0.68 (95% CI, 0.65-0.72). Internal validation by a bootstrap with 200 replications yielded a bias of 0.004, resulting in a nominally lower corrected AUC for both new models. Finally, we used the NRI to compare model 4 to the other models, with an NRI of 0 indicating no difference. Model 4 was an improvement over both comparison models, with an NRI of 24.7% (95% CI, 16.0-33.5) with respect to model 1 and 9.3% (95% CI, 1.1-17.5) with respect to model 2. Model 4 was similar to model 3, with an NRI of 2.7% (95% CI, j3.2 to 8.5).
The distribution of predicted risk by age group for all models is shown in Fig. 1 . We note that the addition of any risk factors other than age and BMD increases the number of younger women classified as low fracture risk (G5% 5-year risk) and simultaneously increases the number of older women classified as very high risk (915% 5-year risk), thus shifting the age distribution of risk categories.
The predicted 5-year fracture risk for women by age, BMD T score, and selected risk profiles using model 4 is shown in Fig. 2 . Women with self-reported excellent health and no prior fracture or other risk factors have a low fracture risk (G5% 5-year risk) over much of the age and osteopenic BMD ranges. The graph also indicates the marked difference in the risk of future fracture between women with and without prior fracture. Prior fracture is associated with a doubling of the risk of future fracture. Women with self-reported good health and prior fracture have a high fracture risk (between 10% and 15% 5-year risk) over much of the age and BMD ranges. Women with self-reported poor health and prior fracture have a very high fracture risk (915% 5-year risk) over much of the age and osteopenic BMD ranges. Finally, we assessed longer term fracture risk by the above-specified 5-year risk categories. The absolute 10-year fracture risk was 8.1% in those with a low 5-year risk, 15.8% in those with a moderate 5-year risk, 20.2% in those with a high 5-year risk, and 32.2% in those with a very high 5-year risk.
DISCUSSION
We developed two new models (models III and IV) for the prediction of 5-year absolute fracture risk among women with osteopenic BMD and compared them with calibrated models based on standard risk factors (model I: age and BMD; model II: the standard WHO clinical risk factors). The new models had a higher risk gradient than the standard models did and showed an improvement in risk classification as assessed by the NRI. The major difference between models III and IV and the standard models is the inclusion of self-reported health status. This inclusion accounts not only for a variety of health conditions as a proxy but also for differences in fracture risk among those without any comorbidities. The general health variable included in model IV FIG. 2. Predicted 5-year absolute fracture risk for selected risk profiles based on model 4. Risk factor profile as given assuming no height loss. Example 1: 70-year-old woman, BMD T score of j1.5, in excellent health, no prior fracture, and no height loss. Using the upper left diagram, we look across from j1.5 and above 70 and see an area shaded white, or low risk. Example 2: 70-year-old woman, BMD T score of j1.5, in good health, with prior fracture, and no height loss. Using the lower middle diagram, we look across from j1.5 and above 70 and see an area shaded dark grey, or high risk.
was also a part of another model predicting hip fracture risk for postmenopausal US women, including those with osteoporosis, suggesting the importance of this variable across populations. 13 Our analysis is not a head-to-head comparison with the FRAX model, as the specific parameters associated with the different variables and interactions within the model are unknown to us. However, we have shown that the variables age, BMD, self-reported health status, and height loss provide improvement in fracture prediction over model II. Our comparison model II includes the same risk factors as the FRAX model but is derived from the study population and, as such, is likely to provide a more optimal classification than the FRAX model itself. One of the assumptions behind the FRAX model is that there is a single best model and that this model can be calibrated to account for known geographic variation in fracture using only hip fracture and mortality data specific to that geographical region. Current country-specific FRAX models indicate substantial betweencountry differences in fracture risk prediction not explained by the model itself. This suggests that the model might be missing important risk factors for fracture and/or that there might be heterogeneity in one or more of the model parameters.
Other researchers have considered the clinical problem of assessing absolute fracture risk in osteopenic women. Our final model includes three of the four clinical markers (age, BMD, and prior fracture) that were found to be important in a cohort of French women with osteopenic BMD. 14 The fourth marker (high bone turnover) was not available in our study and, hence, was not included in any of our models. Our final model also includes variables related to all four of the classifiers noted in a cohort of US women with osteopenia. 15 Previous fracture and BMD were the two first classifiers, whereas general health and mobility were the next two classifiers. Although there are advantages of including continuous measures of physical health, the model with the SF-36 physical component score does not perform much differently than the categorical measure of general health.
We also established that height loss, defined as the difference between measured height and self-reported maximal height, is an independent predictor of future clinical lowtrauma fracture. Height loss (both historical and measured) is an easily assessed proxy for the presence of vertebral fracture. 16, 17 Radiography assessment to determine the presence of vertebral fracture is strongly recommended for those with self-reported height loss regardless of the absolute risk, as vertebral fracture strongly predicts future fracture. 18 Fall history did not appear in our models but was associated with modest but not statistically significant increased risk. A study with similar design found that previous falls were an important independent predictor of absolute fracture risk in men and women without osteoporotic BMD. 19 We note that physical health status is related to some of the underlying factors related to the propensity to fall. Further adjustment of the model might be warranted for those with poor balance but otherwise good health. One possible way to assess underlying fall propensity is to simply ask about balance. 20 Some but not all comorbidities were associated with increased fracture risk, but models including them did not perform better than the main models. It is probable that most diseases modify fracture risk through their effects on BMD 21 and/or health status. 22 Alternatively, the sample size was insufficient to establish a moderate association between comorbidity and fracture risk above that attributable to BMD and/or health status. We note that the SF-36 physical score is also strongly related to other measures including the 6-minute walk test, lower extremity muscle strength, standing balance, gait speed, and chair rise. 23 Thus, if these other measures are available, they may serve as potential surrogates for the SF-36 physical health score or self-rated general health.
We included baseline antiresorptive use as a possible covariate, but models with this variable did not perform better than the main models. Thus, although there was a difference in fracture risk between baseline users and nonusers, the association was not independent of the variables in the model and may be related to both causal and noncausal mechanisms. A previous analysis addressing potential confounding showed that current use of antiresorptive therapy among women older than 50 years was associated with an overall reduction in low-trauma nonvertebral fracture risk but that this reduction might vary by duration and risk subgroups and might be lower among women with no major risk factors (ie, no prior fracture and nonosteoporotic BMD). 24 We note that the assessment of currently available treatments among highrisk osteopenic women should be based on clinical trials including this population.
Recommendations for reporting of BMD in Canada include a simplified classification of absolute risk based on age, BMD, the presence of fragility fracture, and the use of corticosteroids. 25 These profiles are based on fracture data from a Swedish population but have since been validated for Canadian women. 26 Because 10-year risk is roughly double the 5-year risk, model I corresponds well with both the reported risks from the original Swedish data and the Canadian validation. We note that models III and IV show lower fracture risk for those without risk factors who have excellent or very good self-reported general health.
Our study has some limitations. Simple risk assessment models necessarily exclude some important risk factors for a given individual. The cohort included only communitydwelling women at the time of recruitment, and results cannot be generalized to all women. Although the study design used random sampling, the response rate of 42% may also limit generalizability. Fracture outcomes were based on selfreported fracture with a possible ascertainment bias. Those who had a lower risk profile might underreport fracture, particularly vertebral fracture. This would lead to an apparently stronger association between BMD or other risk factors and fracture. Finally, all predictive models should be validated with an independent study sample.
CONCLUSIONS
In summary, we have derived two models (models III and IV) that, upon comparison, yield a better risk stratification than do models with age and BMD alone (model I) or together with clinical risk factors (model II). Our risk diagram provides a fracture prediction over the complete age and BMD ranges and stratified by fracture and health status, thus providing a simple way to determine which women with osteopenia are at low or high risk of fracture. Because these women are mostly found to be at moderate risk of future fractures with the currently available fracture prediction models, the results of our analysis can be used in practice to guide the clinician in further refining fracture risk.
